Inflammation, high-density lipoprotein and cardiovascular dysfunction

Current Opinion in Infectious Diseases

Volumn 24, Issue 3, 2011, Pages 265-272

  Haas, Michael J ^a   Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

endothelium; high density lipoprotein; inflammation; innate immunity; macrophage

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; BASIC FIBROBLAST GROWTH FACTOR; CHOLESTEROL; CYTOKINE RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; I KAPPA B; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PEPTIDOMIMETIC AGENT; PLATELET DERIVED GROWTH FACTOR; RANTES; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL STRESS; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LIPID RAFT; MACROPHAGE ACTIVATION; NONHUMAN; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL;

EID: 79955521121     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328344b724     Document Type: Article

References (74)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis andmanagement of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752. (Pubitemid 41532612)
2. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
3. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apo A-I fractional clearance rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14:707-720.
4. Hardardottie I, Moser AH, Memon R, et al. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res 1994; 13:161-166. (Pubitemid 24206707)
5. Orlov SV, Mogilenko D A, Shavva B S, et al. Effect of TNF alpha on activities of different promoters of human apolipoprotein A-I gene. Biochem Biophys Res Commun 2010; 398:224-230.
6. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009; 206:321-327
7. Surra JC, Guillen N, Arbones-Maiar JM, et al. Sex as a profound modifier of atherosclerotic lesion development in apolipoprotein E-deficient mice with different genetic backgrounds. J Atheroscler Thromb 2010; 17: 712-721.
8. Amar MJ, D?Souza W, Turner S, et al. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 2010; 334:634-641
9. Cimmino G, Chen W, Speidl WS, et al. Safe and sustained over-expression of functional apoA-I/HDL in apoA-I null mice by muscular AAV8 gene transfer. J Cardiovasc Pharmacol 2009; 54:405-411
10. Kleinbongard P, Heusch G, Schulz R. TNF alpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 2010; 127:295-314
11. Szkodzinski J, Blazelonis A, Wilczek K, et al. The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery. Int J Immunopathol Pharmacol 2009; 22:493-500.
12. Keavney B. The interleukin-1 cluster, dyslipidaemia, and risk of myocardial infarction. BMC Med 2010; 8:6
13. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109:745-753. (Pubitemid 34263151)
14. Bennermo M, Nordin M, Lundman P, et al. Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study. J Interferon Cytokine Res 2010 [Epub ahead of print]
15. Heiskanen M, Kahonen M, Hurme M, et al. Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the cardiovascular risk in young Finns study. Atherosclerosis 2010; 208:190-196.
16. Hernesniemi JA, Anttila K, Nieminen T, et al. IL-18 gene polymorphism, cardiovascular mortality, and coronary artery disease. Eur J Clin Invest 2010; 40:994-1001
17. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109:2186-2190. (Pubitemid 38625395)
18. Sigala F, Savvari P, Liontos M, et al. Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-kappaB pathway. J Cell Mol Med 2010 [Epub ahead of print]
19. Van Brussel I, Van Vre EA, De Meyer GR, et al. Decreased numbers of peripheral blood dendritic cells in patients with coronary artery disease are associated with diminished plasma Flt3 ligand levels and impaired plasmacytoid dendritic cell function. Clin Sci 2011; 120:415-426.
20. Pedersen ER, Midttun O, Ueland PM, et al. Systemic markers of interferon-gmediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2010; 137:1275-1284.
21. Lee YH, Lee SH, Jung ES, et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 2010; 213:592-597.
22. Jandt E, Mutschke O, Mahboobi S, et al. Stent-based release of a selective PDGF-receptor blocker from the bis-indolylmethanon class inhibits restenosis in the rabbit animal model. Vascul Pharmacol 2010; 52:55-62.
23. Quercioli A, Montecucco F, Bertolotto M, et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signaling. Eur J Clin Invest 2010; 40:645-654.
24. Holm PW, Slart RH, Zeebregts CJ, et al. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 2009; 41:257-264
25. Sethi B, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 2008; 13:5094-5107. (Pubitemid 351599660)
26. Patial S, Parameswaran N. Tumor necrosis factor-a signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20:87-103.
27. Wang YF, Yang XF, Cheng B, et al. Protective effect of astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha. Phytother Res 2010; 24:393-398.
28. Gergod-Giannone MC, Li Y, Holleboom A, et al. TNFalpha induces ABCA1 through NF-kB in macrophages and in phagocytes ingesting apoptotic cells. Proc Natl Acad Sci U S A 2006; 103:3112-3117. (Pubitemid 43346433)
29. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15:1987-1994.
30. Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95:764-772. (Pubitemid 39390578)
31. Bobryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron 2006; 37:208-222. (Pubitemid 43106595)
32. Bursill CA, Castro ML, Beattie DT, et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010; 30:1773-1778.
33. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28:2071-2077.
34. Zhu X, Lee JY, Timmins JM, et al. Increased cellular free-cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008; 283:22930-22941.
35. Landry YD, Denis M, Nandi S, et al. ATP-binding cassette transporter AI expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem 2006; 281:36091-36101. (Pubitemid 46041342)
36. Tellier E, Canault M, Poggi M, et al. HDLs activate ADAM17-dependent shedding. J Cell Physiol 2008; 214:687-693. (Pubitemid 351224213)
37. Takaguri A, Shirai H, Kimura K, et al. Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J Mol Cell Cardiol 2010 [Epub ahead of print].
38. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010; 30:139-143.
39. Tang C, Liu Y, Kessler PS, et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009; 284:32336-32343
40. Cai L, Ji A, de Beer FC, et al. SR-B1 protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008; 118:364-375.
41. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328:1689-1693.
42. Ikemoto M, Arai H, Feng D, et al. Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I. Proc Natl Acad Sci U S A 2000; 97:6538-6543. (Pubitemid 30412749)
43. Silver DL. A carboxy-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in the liver. J Biol Chem 2002; 277:34042-34047.
44. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science 1996; 271:518-520.
45. Kocher O, Yesilaltay A, Cirovic C, et al. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high-density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J Biol Chem 2003; 278:52820-52825. (Pubitemid 38035880)
46. Gong M, Wilson M, Kelley T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003; 111:1579-1587. (Pubitemid 38063291)
47. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113:569-581. (Pubitemid 38542506)
48. Kimura T, Tomura H, Mogi C, et al. Role of scavenger receptor class B type I and sphingosine-1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 2006; 281:37457-37467. (Pubitemid 46042049)
49. Yeh CC, Li H, Malhotra D, et al. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296:H1193-H1199.
50. Balogh S, Kiss I, Csaszar A. Toll-like receptors: link between ?danger? ligands and plaque instability. Curr Drug Targets 2009; 10:513-516.
51. Harrington LS, Belcher E, Moreno L, et al. Homeostatic role of Toll-like receptor 4 in the endothelium and heart. J Cardiovasc Pharmacol Ther 2007; 12:322-326. (Pubitemid 350264692)
52. Zhang X, Shan P, Jiang G, et al. Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest 2006; 116:3050-3059. (Pubitemid 44684490)
53. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin-hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191. (Pubitemid 30394990)
54. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192. (Pubitemid 34764822)
55. Ameziane N, Beillat T, Verpillat P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23:pe61-pe64.
56. Edfeldt K, Bennet AM, Eriksson P, et al. Association of hypo-responsive tolllike receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25:1447-1453. (Pubitemid 39078252)
57. Labrum R, Bevan S, Sitzer M, et al. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007; 38:1179-1184. (Pubitemid 351664263)
58. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107:2416-2421. (Pubitemid 36605222)
59. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90: 12040-12044. (Pubitemid 24008776)
60. Hubsch AP, Casas AT, Doran JE. Protective effect of reconstituted highdensity lipoprotein in rabbit Gram-negative bacteremia models. J Lab Clin Med 1995; 126:548-558.
61. Zhang ZG, Datta Y, Zhang AP, et al. Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol 2009; 297:H866-H873.
62. Birjmohun RS, van Leuven SI, Levels JH, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007; 27:1153-1158. (Pubitemid 46641971)
63. Feingold KR, Funk JL, Moser AH, et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63:2041-2046.
64. Charakida M, Besler C, Batuca JR, et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009; 302:1210-1217
65. Hu W, Abe-Dohmae S, Tsujita M, et al. Biogenesis of high density lipoprotein by serum amyloid A is dependent on ATP binding cassette transporter A-I in the liver in vivo. J Lipid Res 2008; 49:386-393.
66. Skaggs BJ, Hahn BH, Sahakian L, et al. Dysfunctional, pro-inflammatory HDL directly upregulates monocytes PDGFb, chemotaxis and TNFa production. Clin Immunol 2010; 137:147-156
67. Shao B, Pennathur S, Pagani J, et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 2010; 285:18473-18484
68. Shao B, Tang C, Heinecke JW. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 2010; 51:1849-1858.
69. Datta G, White CR, Dashti N, et al. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2. Atherosclerosis 2010; 208:134-141
70. Dai L, Datta G, Zhang Z, et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J Lipid Res 2010; 51:2695-2705.
71. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009; 53:962-971.
72. Nandedkar SD, Weihrach D, Xu H, et al. D-4F, an apoA-I mimetic, decreases airway hyper-responsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res 2010 [Epub ahead of print].
73. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010; 6:287-296.
74. Vaziri ND, Moradi H, Pahl MV, et al. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of end-stage renal disease by an apoA-I mimetic peptide. Kidney Int 2009; 76:437-444.